Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Gaurab Chakrabarti; Molly A. Silvers; Mariya Ilcheva; Yuliang Liu; Zachary R. Moore; Xiuquan Luo; Jinming Gao; Glenda Anderson; Lili Liu; Venetia Sarode; David E. Gerber; Sandeep Burma; Ralph J. DeBerardinis; Stanton L. Gerson; David A. Boothman

doi:10.1038/srep17066

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Gaurab Chakrabarti, Molly A. Silvers, Mariya Ilcheva, Yuliang Liu, Zachary R. Moore, Xiuquan Luo, Jinming Gao, Glenda Anderson, Lili Liu, Venetia Sarode, David E. Gerber, Sandeep Burma, Ralph J. DeBerardinis, Stanton L. Gerson, David A. Boothman

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, β-lapachone (ARQ761 in clinical form), can provide tumor-selective and enhanced synergy with BER inhibition. β-Lapachone undergoes NQO1-dependent futile redox cycling, generating massive intracellular hydrogen peroxide levels and oxidative DNA lesions that stimulate poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. Rapid NAD⁺/ATP depletion and programmed necrosis results. To identify BER modulators essential for repair of β-lapachone-induced DNA base damage, a focused synthetic lethal RNAi screen demonstrated that silencing the BER scaffolding protein, XRCC1, sensitized PDA cells. In contrast, depleting OGG1 N-glycosylase spared cells from β-lap-induced lethality and blunted PARP1 hyperactivation. Combining β-lapachone with XRCC1 knockdown or methoxyamine (MeOX), an apyrimidinic/apurinic (AP)-modifying agent, led to NQO1-dependent synergistic killing in PDA, NSCLC, breast and head and neck cancers. OGG1 knockdown, dicoumarol-treatment or NQO1- cancer cells were spared. MeOX + β-lapachone exposure resulted in elevated DNA double-strand breaks, PARP1 hyperactivation and TUNEL+ programmed necrosis. Combination treatment caused dramatic antitumor activity, enhanced PARP1-hyperactivation in tumor tissue, and improved survival of mice bearing MiaPaca2-derived xenografts, with 33% apparent cures. Significance: Targeting base excision repair (BER) alone has limited therapeutic potential for pancreatic or other cancers due to a general lack of tumor-selectivity. Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.

Original language	English (US)
Article number	17066
Journal	Scientific reports
Volume	5
DOIs	https://doi.org/10.1038/srep17066
State	Published - Nov 25 2015

ASJC Scopus subject areas

General

Access to Document

10.1038/srep17066

Cite this

Chakrabarti, G., Silvers, M. A., Ilcheva, M., Liu, Y., Moore, Z. R., Luo, X., Gao, J., Anderson, G., Liu, L., Sarode, V., Gerber, D. E., Burma, S., DeBerardinis, R. J., Gerson, S. L., & Boothman, D. A. (2015). Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone. Scientific reports, 5, Article 17066. https://doi.org/10.1038/srep17066

Chakrabarti, G, Silvers, MA, Ilcheva, M, Liu, Y, Moore, ZR, Luo, X, Gao, J, Anderson, G, Liu, L, Sarode, V, Gerber, DE, Burma, S, DeBerardinis, RJ, Gerson, SL & Boothman, DA 2015, 'Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone', Scientific reports, vol. 5, 17066. https://doi.org/10.1038/srep17066

@article{0c360a1bbf27470b97a0a7e555bef8c9,

title = "Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone",

abstract = "Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, β-lapachone (ARQ761 in clinical form), can provide tumor-selective and enhanced synergy with BER inhibition. β-Lapachone undergoes NQO1-dependent futile redox cycling, generating massive intracellular hydrogen peroxide levels and oxidative DNA lesions that stimulate poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. Rapid NAD+/ATP depletion and programmed necrosis results. To identify BER modulators essential for repair of β-lapachone-induced DNA base damage, a focused synthetic lethal RNAi screen demonstrated that silencing the BER scaffolding protein, XRCC1, sensitized PDA cells. In contrast, depleting OGG1 N-glycosylase spared cells from β-lap-induced lethality and blunted PARP1 hyperactivation. Combining β-lapachone with XRCC1 knockdown or methoxyamine (MeOX), an apyrimidinic/apurinic (AP)-modifying agent, led to NQO1-dependent synergistic killing in PDA, NSCLC, breast and head and neck cancers. OGG1 knockdown, dicoumarol-treatment or NQO1- cancer cells were spared. MeOX + β-lapachone exposure resulted in elevated DNA double-strand breaks, PARP1 hyperactivation and TUNEL+ programmed necrosis. Combination treatment caused dramatic antitumor activity, enhanced PARP1-hyperactivation in tumor tissue, and improved survival of mice bearing MiaPaca2-derived xenografts, with 33% apparent cures. Significance: Targeting base excision repair (BER) alone has limited therapeutic potential for pancreatic or other cancers due to a general lack of tumor-selectivity. Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.",

author = "Gaurab Chakrabarti and Silvers, {Molly A.} and Mariya Ilcheva and Yuliang Liu and Moore, {Zachary R.} and Xiuquan Luo and Jinming Gao and Glenda Anderson and Lili Liu and Venetia Sarode and Gerber, {David E.} and Sandeep Burma and DeBerardinis, {Ralph J.} and Gerson, {Stanton L.} and Boothman, {David A.}",

year = "2015",

month = nov,

day = "25",

doi = "10.1038/srep17066",

language = "English (US)",

volume = "5",

journal = "Scientific reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

AU - Chakrabarti, Gaurab

AU - Silvers, Molly A.

AU - Ilcheva, Mariya

AU - Liu, Yuliang

AU - Moore, Zachary R.

AU - Luo, Xiuquan

AU - Gao, Jinming

AU - Anderson, Glenda

AU - Liu, Lili

AU - Sarode, Venetia

AU - Gerber, David E.

AU - Burma, Sandeep

AU - DeBerardinis, Ralph J.

AU - Gerson, Stanton L.

AU - Boothman, David A.

PY - 2015/11/25

Y1 - 2015/11/25

N2 - Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, β-lapachone (ARQ761 in clinical form), can provide tumor-selective and enhanced synergy with BER inhibition. β-Lapachone undergoes NQO1-dependent futile redox cycling, generating massive intracellular hydrogen peroxide levels and oxidative DNA lesions that stimulate poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. Rapid NAD+/ATP depletion and programmed necrosis results. To identify BER modulators essential for repair of β-lapachone-induced DNA base damage, a focused synthetic lethal RNAi screen demonstrated that silencing the BER scaffolding protein, XRCC1, sensitized PDA cells. In contrast, depleting OGG1 N-glycosylase spared cells from β-lap-induced lethality and blunted PARP1 hyperactivation. Combining β-lapachone with XRCC1 knockdown or methoxyamine (MeOX), an apyrimidinic/apurinic (AP)-modifying agent, led to NQO1-dependent synergistic killing in PDA, NSCLC, breast and head and neck cancers. OGG1 knockdown, dicoumarol-treatment or NQO1- cancer cells were spared. MeOX + β-lapachone exposure resulted in elevated DNA double-strand breaks, PARP1 hyperactivation and TUNEL+ programmed necrosis. Combination treatment caused dramatic antitumor activity, enhanced PARP1-hyperactivation in tumor tissue, and improved survival of mice bearing MiaPaca2-derived xenografts, with 33% apparent cures. Significance: Targeting base excision repair (BER) alone has limited therapeutic potential for pancreatic or other cancers due to a general lack of tumor-selectivity. Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.

AB - Base excision repair (BER) is an essential pathway for pancreatic ductal adenocarcinoma (PDA) survival. Attempts to target this repair pathway have failed due to lack of tumor-selectivity and very limited efficacy. The NAD(P)H:Quinone Oxidoreductase 1 (NQO1) bioactivatable drug, β-lapachone (ARQ761 in clinical form), can provide tumor-selective and enhanced synergy with BER inhibition. β-Lapachone undergoes NQO1-dependent futile redox cycling, generating massive intracellular hydrogen peroxide levels and oxidative DNA lesions that stimulate poly(ADP-ribose) polymerase 1 (PARP1) hyperactivation. Rapid NAD+/ATP depletion and programmed necrosis results. To identify BER modulators essential for repair of β-lapachone-induced DNA base damage, a focused synthetic lethal RNAi screen demonstrated that silencing the BER scaffolding protein, XRCC1, sensitized PDA cells. In contrast, depleting OGG1 N-glycosylase spared cells from β-lap-induced lethality and blunted PARP1 hyperactivation. Combining β-lapachone with XRCC1 knockdown or methoxyamine (MeOX), an apyrimidinic/apurinic (AP)-modifying agent, led to NQO1-dependent synergistic killing in PDA, NSCLC, breast and head and neck cancers. OGG1 knockdown, dicoumarol-treatment or NQO1- cancer cells were spared. MeOX + β-lapachone exposure resulted in elevated DNA double-strand breaks, PARP1 hyperactivation and TUNEL+ programmed necrosis. Combination treatment caused dramatic antitumor activity, enhanced PARP1-hyperactivation in tumor tissue, and improved survival of mice bearing MiaPaca2-derived xenografts, with 33% apparent cures. Significance: Targeting base excision repair (BER) alone has limited therapeutic potential for pancreatic or other cancers due to a general lack of tumor-selectivity. Here, we present a treatment strategy that makes BER inhibition tumor-selective and NQO1-dependent for therapy of most solid neoplasms, particularly for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84948171903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948171903&partnerID=8YFLogxK

U2 - 10.1038/srep17066

DO - 10.1038/srep17066

M3 - Article

C2 - 26602448

AN - SCOPUS:84948171903

SN - 2045-2322

VL - 5

JO - Scientific reports

JF - Scientific reports

M1 - 17066

ER -

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this